IL
Illinois Senate Bill SB2089

Illinois 2023-2024 Regular Session

Illinois Senate Bill SB2089 Compare Versions

Only one version of the bill is available at this time.
OldNewDifferences
11 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB2089 Introduced 2/9/2023, by Sen. Patrick J. Joyce SYNOPSIS AS INTRODUCED: 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/401 from Ch. 56 1/2, par. 1401 Amends the Illinois Controlled Substances Act. Adds xylazine as a Schedule I controlled substance. Provides for penalties for the knowing manufacture or delivery, or possession with intent to manufacture or deliver xylazine. LRB103 27669 RLC 57233 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB2089 Introduced 2/9/2023, by Sen. Patrick J. Joyce SYNOPSIS AS INTRODUCED: 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/401 from Ch. 56 1/2, par. 1401 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/401 from Ch. 56 1/2, par. 1401 Amends the Illinois Controlled Substances Act. Adds xylazine as a Schedule I controlled substance. Provides for penalties for the knowing manufacture or delivery, or possession with intent to manufacture or deliver xylazine. LRB103 27669 RLC 57233 b LRB103 27669 RLC 57233 b A BILL FOR
22 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB2089 Introduced 2/9/2023, by Sen. Patrick J. Joyce SYNOPSIS AS INTRODUCED:
33 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/401 from Ch. 56 1/2, par. 1401 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/401 from Ch. 56 1/2, par. 1401
44 720 ILCS 570/204 from Ch. 56 1/2, par. 1204
55 720 ILCS 570/401 from Ch. 56 1/2, par. 1401
66 Amends the Illinois Controlled Substances Act. Adds xylazine as a Schedule I controlled substance. Provides for penalties for the knowing manufacture or delivery, or possession with intent to manufacture or deliver xylazine.
77 LRB103 27669 RLC 57233 b LRB103 27669 RLC 57233 b
88 LRB103 27669 RLC 57233 b
99 A BILL FOR
1010 SB2089LRB103 27669 RLC 57233 b SB2089 LRB103 27669 RLC 57233 b
1111 SB2089 LRB103 27669 RLC 57233 b
1212 1 AN ACT concerning criminal law.
1313 2 Be it enacted by the People of the State of Illinois,
1414 3 represented in the General Assembly:
1515 4 Section 5. The Illinois Controlled Substances Act is
1616 5 amended by changing Sections 204 and 401 as follows:
1717 6 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
1818 7 Sec. 204. (a) The controlled substances listed in this
1919 8 Section are included in Schedule I.
2020 9 (b) Unless specifically excepted or unless listed in
2121 10 another schedule, any of the following opiates, including
2222 11 their isomers, esters, ethers, salts, and salts of isomers,
2323 12 esters, and ethers, whenever the existence of such isomers,
2424 13 esters, ethers and salts is possible within the specific
2525 14 chemical designation:
2626 15 (1) Acetylmethadol;
2727 16 (1.1) Acetyl-alpha-methylfentanyl
2828 17 (N-[1-(1-methyl-2-phenethyl)-
2929 18 4-piperidinyl]-N-phenylacetamide);
3030 19 (2) Allylprodine;
3131 20 (3) Alphacetylmethadol, except
3232 21 levo-alphacetylmethadol (also known as levo-alpha-
3333 22 acetylmethadol, levomethadyl acetate, or LAAM);
3434 23 (4) Alphameprodine;
3535
3636
3737
3838 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB2089 Introduced 2/9/2023, by Sen. Patrick J. Joyce SYNOPSIS AS INTRODUCED:
3939 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/401 from Ch. 56 1/2, par. 1401 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/401 from Ch. 56 1/2, par. 1401
4040 720 ILCS 570/204 from Ch. 56 1/2, par. 1204
4141 720 ILCS 570/401 from Ch. 56 1/2, par. 1401
4242 Amends the Illinois Controlled Substances Act. Adds xylazine as a Schedule I controlled substance. Provides for penalties for the knowing manufacture or delivery, or possession with intent to manufacture or deliver xylazine.
4343 LRB103 27669 RLC 57233 b LRB103 27669 RLC 57233 b
4444 LRB103 27669 RLC 57233 b
4545 A BILL FOR
4646
4747
4848
4949
5050
5151 720 ILCS 570/204 from Ch. 56 1/2, par. 1204
5252 720 ILCS 570/401 from Ch. 56 1/2, par. 1401
5353
5454
5555
5656 LRB103 27669 RLC 57233 b
5757
5858
5959
6060
6161
6262
6363
6464
6565
6666 SB2089 LRB103 27669 RLC 57233 b
6767
6868
6969 SB2089- 2 -LRB103 27669 RLC 57233 b SB2089 - 2 - LRB103 27669 RLC 57233 b
7070 SB2089 - 2 - LRB103 27669 RLC 57233 b
7171 1 (5) Alphamethadol;
7272 2 (6) Alpha-methylfentanyl
7373 3 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
7474 4 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
7575 5 propanilido) piperidine;
7676 6 (6.1) Alpha-methylthiofentanyl
7777 7 (N-[1-methyl-2-(2-thienyl)ethyl-
7878 8 4-piperidinyl]-N-phenylpropanamide);
7979 9 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
8080 10 (7.1) PEPAP
8181 11 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
8282 12 (8) Benzethidine;
8383 13 (9) Betacetylmethadol;
8484 14 (9.1) Beta-hydroxyfentanyl
8585 15 (N-[1-(2-hydroxy-2-phenethyl)-
8686 16 4-piperidinyl]-N-phenylpropanamide);
8787 17 (10) Betameprodine;
8888 18 (11) Betamethadol;
8989 19 (12) Betaprodine;
9090 20 (13) Clonitazene;
9191 21 (14) Dextromoramide;
9292 22 (15) Diampromide;
9393 23 (16) Diethylthiambutene;
9494 24 (17) Difenoxin;
9595 25 (18) Dimenoxadol;
9696 26 (19) Dimepheptanol;
9797
9898
9999
100100
101101
102102 SB2089 - 2 - LRB103 27669 RLC 57233 b
103103
104104
105105 SB2089- 3 -LRB103 27669 RLC 57233 b SB2089 - 3 - LRB103 27669 RLC 57233 b
106106 SB2089 - 3 - LRB103 27669 RLC 57233 b
107107 1 (20) Dimethylthiambutene;
108108 2 (21) Dioxaphetylbutyrate;
109109 3 (22) Dipipanone;
110110 4 (23) Ethylmethylthiambutene;
111111 5 (24) Etonitazene;
112112 6 (25) Etoxeridine;
113113 7 (26) Furethidine;
114114 8 (27) Hydroxpethidine;
115115 9 (28) Ketobemidone;
116116 10 (29) Levomoramide;
117117 11 (30) Levophenacylmorphan;
118118 12 (31) 3-Methylfentanyl
119119 13 (N-[3-methyl-1-(2-phenylethyl)-
120120 14 4-piperidyl]-N-phenylpropanamide);
121121 15 (31.1) 3-Methylthiofentanyl
122122 16 (N-[(3-methyl-1-(2-thienyl)ethyl-
123123 17 4-piperidinyl]-N-phenylpropanamide);
124124 18 (32) Morpheridine;
125125 19 (33) Noracymethadol;
126126 20 (34) Norlevorphanol;
127127 21 (35) Normethadone;
128128 22 (36) Norpipanone;
129129 23 (36.1) Para-fluorofentanyl
130130 24 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
131131 25 4-piperidinyl]propanamide);
132132 26 (37) Phenadoxone;
133133
134134
135135
136136
137137
138138 SB2089 - 3 - LRB103 27669 RLC 57233 b
139139
140140
141141 SB2089- 4 -LRB103 27669 RLC 57233 b SB2089 - 4 - LRB103 27669 RLC 57233 b
142142 SB2089 - 4 - LRB103 27669 RLC 57233 b
143143 1 (38) Phenampromide;
144144 2 (39) Phenomorphan;
145145 3 (40) Phenoperidine;
146146 4 (41) Piritramide;
147147 5 (42) Proheptazine;
148148 6 (43) Properidine;
149149 7 (44) Propiram;
150150 8 (45) Racemoramide;
151151 9 (45.1) Thiofentanyl
152152 10 (N-phenyl-N-[1-(2-thienyl)ethyl-
153153 11 4-piperidinyl]-propanamide);
154154 12 (46) Tilidine;
155155 13 (47) Trimeperidine;
156156 14 (48) Beta-hydroxy-3-methylfentanyl (other name:
157157 15 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
158158 16 N-phenylpropanamide);
159159 17 (49) Furanyl fentanyl (FU-F);
160160 18 (50) Butyryl fentanyl;
161161 19 (51) Valeryl fentanyl;
162162 20 (52) Acetyl fentanyl;
163163 21 (53) Beta-hydroxy-thiofentanyl;
164164 22 (54) 3,4-dichloro-N-[2-
165165 23 (dimethylamino)cyclohexyl]-N-
166166 24 methylbenzamide (U-47700);
167167 25 (55) 4-chloro-N-[1-[2-
168168 26 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
169169
170170
171171
172172
173173
174174 SB2089 - 4 - LRB103 27669 RLC 57233 b
175175
176176
177177 SB2089- 5 -LRB103 27669 RLC 57233 b SB2089 - 5 - LRB103 27669 RLC 57233 b
178178 SB2089 - 5 - LRB103 27669 RLC 57233 b
179179 1 benzenesulfonamide (W-18);
180180 2 (56) 4-chloro-N-[1-(2-phenylethyl)
181181 3 -2-piperidinylidene]-benzenesulfonamide (W-15);
182182 4 (57) acrylfentanyl (acryloylfentanyl).
183183 5 (c) Unless specifically excepted or unless listed in
184184 6 another schedule, any of the following opium derivatives, its
185185 7 salts, isomers and salts of isomers, whenever the existence of
186186 8 such salts, isomers and salts of isomers is possible within
187187 9 the specific chemical designation:
188188 10 (1) Acetorphine;
189189 11 (2) Acetyldihydrocodeine;
190190 12 (3) Benzylmorphine;
191191 13 (4) Codeine methylbromide;
192192 14 (5) Codeine-N-Oxide;
193193 15 (6) Cyprenorphine;
194194 16 (7) Desomorphine;
195195 17 (8) Diacetyldihydromorphine (Dihydroheroin);
196196 18 (9) Dihydromorphine;
197197 19 (10) Drotebanol;
198198 20 (11) Etorphine (except hydrochloride salt);
199199 21 (12) Heroin;
200200 22 (13) Hydromorphinol;
201201 23 (14) Methyldesorphine;
202202 24 (15) Methyldihydromorphine;
203203 25 (16) Morphine methylbromide;
204204 26 (17) Morphine methylsulfonate;
205205
206206
207207
208208
209209
210210 SB2089 - 5 - LRB103 27669 RLC 57233 b
211211
212212
213213 SB2089- 6 -LRB103 27669 RLC 57233 b SB2089 - 6 - LRB103 27669 RLC 57233 b
214214 SB2089 - 6 - LRB103 27669 RLC 57233 b
215215 1 (18) Morphine-N-Oxide;
216216 2 (19) Myrophine;
217217 3 (20) Nicocodeine;
218218 4 (21) Nicomorphine;
219219 5 (22) Normorphine;
220220 6 (23) Pholcodine;
221221 7 (24) Thebacon.
222222 8 (d) Unless specifically excepted or unless listed in
223223 9 another schedule, any material, compound, mixture, or
224224 10 preparation which contains any quantity of the following
225225 11 hallucinogenic substances, or which contains any of its salts,
226226 12 isomers and salts of isomers, whenever the existence of such
227227 13 salts, isomers, and salts of isomers is possible within the
228228 14 specific chemical designation (for the purposes of this
229229 15 paragraph only, the term "isomer" includes the optical,
230230 16 position and geometric isomers):
231231 17 (1) 3,4-methylenedioxyamphetamine
232232 18 (alpha-methyl,3,4-methylenedioxyphenethylamine,
233233 19 methylenedioxyamphetamine, MDA);
234234 20 (1.1) Alpha-ethyltryptamine
235235 21 (some trade or other names: etryptamine;
236236 22 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
237237 23 3-(2-aminobutyl)indole; a-ET; and AET);
238238 24 (2) 3,4-methylenedioxymethamphetamine (MDMA);
239239 25 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
240240 26 (also known as: N-ethyl-alpha-methyl-
241241
242242
243243
244244
245245
246246 SB2089 - 6 - LRB103 27669 RLC 57233 b
247247
248248
249249 SB2089- 7 -LRB103 27669 RLC 57233 b SB2089 - 7 - LRB103 27669 RLC 57233 b
250250 SB2089 - 7 - LRB103 27669 RLC 57233 b
251251 1 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
252252 2 and MDEA);
253253 3 (2.2) N-Benzylpiperazine (BZP);
254254 4 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
255255 5 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
256256 6 (4) 3,4,5-trimethoxyamphetamine (TMA);
257257 7 (5) (Blank);
258258 8 (6) Diethyltryptamine (DET);
259259 9 (7) Dimethyltryptamine (DMT);
260260 10 (7.1) 5-Methoxy-diallyltryptamine;
261261 11 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
262262 12 (9) Ibogaine (some trade and other names:
263263 13 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
264264 14 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
265265 15 indole; Tabernanthe iboga);
266266 16 (10) Lysergic acid diethylamide;
267267 17 (10.1) Salvinorin A;
268268 18 (10.5) Salvia divinorum (meaning all parts of the
269269 19 plant presently classified botanically as Salvia
270270 20 divinorum, whether growing or not, the seeds thereof, any
271271 21 extract from any part of that plant, and every compound,
272272 22 manufacture, salts, isomers, and salts of isomers whenever
273273 23 the existence of such salts, isomers, and salts of isomers
274274 24 is possible within the specific chemical designation,
275275 25 derivative, mixture, or preparation of that plant, its
276276 26 seeds or extracts);
277277
278278
279279
280280
281281
282282 SB2089 - 7 - LRB103 27669 RLC 57233 b
283283
284284
285285 SB2089- 8 -LRB103 27669 RLC 57233 b SB2089 - 8 - LRB103 27669 RLC 57233 b
286286 SB2089 - 8 - LRB103 27669 RLC 57233 b
287287 1 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
288288 2 (12) Peyote (meaning all parts of the plant presently
289289 3 classified botanically as Lophophora williamsii Lemaire,
290290 4 whether growing or not, the seeds thereof, any extract
291291 5 from any part of that plant, and every compound,
292292 6 manufacture, salts, derivative, mixture, or preparation of
293293 7 that plant, its seeds or extracts);
294294 8 (13) N-ethyl-3-piperidyl benzilate (JB 318);
295295 9 (14) N-methyl-3-piperidyl benzilate;
296296 10 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
297297 11 (also known as N-hydroxy-alpha-methyl-
298298 12 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
299299 13 (15) Parahexyl; some trade or other names:
300300 14 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
301301 15 dibenzo (b,d) pyran; Synhexyl;
302302 16 (16) Psilocybin;
303303 17 (17) Psilocyn;
304304 18 (18) Alpha-methyltryptamine (AMT);
305305 19 (19) 2,5-dimethoxyamphetamine
306306 20 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
307307 21 (20) 4-bromo-2,5-dimethoxyamphetamine
308308 22 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
309309 23 4-bromo-2,5-DMA);
310310 24 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
311311 25 Some trade or other names: 2-(4-bromo-
312312 26 2,5-dimethoxyphenyl)-1-aminoethane;
313313
314314
315315
316316
317317
318318 SB2089 - 8 - LRB103 27669 RLC 57233 b
319319
320320
321321 SB2089- 9 -LRB103 27669 RLC 57233 b SB2089 - 9 - LRB103 27669 RLC 57233 b
322322 SB2089 - 9 - LRB103 27669 RLC 57233 b
323323 1 alpha-desmethyl DOB, 2CB, Nexus;
324324 2 (21) 4-methoxyamphetamine
325325 3 (4-methoxy-alpha-methylphenethylamine;
326326 4 paramethoxyamphetamine; PMA);
327327 5 (22) (Blank);
328328 6 (23) Ethylamine analog of phencyclidine.
329329 7 Some trade or other names:
330330 8 N-ethyl-1-phenylcyclohexylamine,
331331 9 (1-phenylcyclohexyl) ethylamine,
332332 10 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
333333 11 (24) Pyrrolidine analog of phencyclidine. Some trade
334334 12 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
335335 13 PHP;
336336 14 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
337337 15 (26) 2,5-dimethoxy-4-ethylamphetamine
338338 16 (another name: DOET);
339339 17 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
340340 18 (another name: TCPy);
341341 19 (28) (Blank);
342342 20 (29) Thiophene analog of phencyclidine (some trade
343343 21 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
344344 22 2-thienyl analog of phencyclidine; TPCP; TCP);
345345 23 (29.1) Benzothiophene analog of phencyclidine. Some
346346 24 trade or other names: BTCP or benocyclidine;
347347 25 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
348348 26 (30) Bufotenine (some trade or other names:
349349
350350
351351
352352
353353
354354 SB2089 - 9 - LRB103 27669 RLC 57233 b
355355
356356
357357 SB2089- 10 -LRB103 27669 RLC 57233 b SB2089 - 10 - LRB103 27669 RLC 57233 b
358358 SB2089 - 10 - LRB103 27669 RLC 57233 b
359359 1 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
360360 2 3-(2-dimethylaminoethyl)-5-indolol;
361361 3 5-hydroxy-N,N-dimethyltryptamine;
362362 4 N,N-dimethylserotonin; mappine);
363363 5 (31) (Blank);
364364 6 (32) (Blank);
365365 7 (33) (Blank);
366366 8 (34) (Blank);
367367 9 (34.5) (Blank);
368368 10 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
369369 11 (2-methyloctan-2-yl)-6a,7,
370370 12 10,10a-tetrahydrobenzo[c]chromen-1-ol
371371 13 Some trade or other names: HU-210;
372372 14 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
373373 15 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
374374 16 tetrahydrobenzo[c]chromen-1-ol, its isomers,
375375 17 salts, and salts of isomers; Some trade or other
376376 18 names: HU-210, Dexanabinol;
377377 19 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
378378 20 6,6-dimethyl-3-(2-methyloctan-2-yl)-
379379 21 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
380380 22 Some trade or other names: HU-211;
381381 23 (37) (Blank);
382382 24 (38) (Blank);
383383 25 (39) (Blank);
384384 26 (40) (Blank);
385385
386386
387387
388388
389389
390390 SB2089 - 10 - LRB103 27669 RLC 57233 b
391391
392392
393393 SB2089- 11 -LRB103 27669 RLC 57233 b SB2089 - 11 - LRB103 27669 RLC 57233 b
394394 SB2089 - 11 - LRB103 27669 RLC 57233 b
395395 1 (41) (Blank);
396396 2 (42) Any compound structurally derived from
397397 3 3-(1-naphthoyl)indole or
398398 4 1H-indol-3-yl-(1-naphthyl)methane by substitution at the
399399 5 nitrogen atom of the indole ring by alkyl, haloalkyl,
400400 6 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
401401 7 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
402402 8 2-(4-morpholinyl)ethyl whether or not further substituted
403403 9 in the indole ring to any extent, whether or not
404404 10 substituted in the naphthyl ring to any extent. Examples
405405 11 of this structural class include, but are not limited to,
406406 12 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
407407 13 (43) Any compound structurally derived from
408408 14 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
409409 15 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
410410 16 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
411411 17 halide, 1-(N-methyl-2-piperidinyl)methyl, or
412412 18 2-(4-morpholinyl)ethyl, whether or not further substituted
413413 19 in the pyrrole ring to any extent, whether or not
414414 20 substituted in the naphthyl ring to any extent. Examples
415415 21 of this structural class include, but are not limited to,
416416 22 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
417417 23 (44) Any compound structurally derived from
418418 24 1-(1-naphthylmethyl)indene by substitution at the
419419 25 3-position of the indene ring by alkyl, haloalkyl,
420420 26 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
421421
422422
423423
424424
425425
426426 SB2089 - 11 - LRB103 27669 RLC 57233 b
427427
428428
429429 SB2089- 12 -LRB103 27669 RLC 57233 b SB2089 - 12 - LRB103 27669 RLC 57233 b
430430 SB2089 - 12 - LRB103 27669 RLC 57233 b
431431 1 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
432432 2 2-(4-morpholinyl)ethyl whether or not further substituted
433433 3 in the indene ring to any extent, whether or not
434434 4 substituted in the naphthyl ring to any extent. Examples
435435 5 of this structural class include, but are not limited to,
436436 6 JWH-176;
437437 7 (45) Any compound structurally derived from
438438 8 3-phenylacetylindole by substitution at the nitrogen atom
439439 9 of the indole ring with alkyl, haloalkyl, alkenyl,
440440 10 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
441441 11 halide, 1-(N-methyl-2-piperidinyl)methyl, or
442442 12 2-(4-morpholinyl)ethyl, whether or not further substituted
443443 13 in the indole ring to any extent, whether or not
444444 14 substituted in the phenyl ring to any extent. Examples of
445445 15 this structural class include, but are not limited to,
446446 16 JWH-167, JWH-250, JWH-251, and RCS-8;
447447 17 (46) Any compound structurally derived from
448448 18 2-(3-hydroxycyclohexyl)phenol by substitution at the
449449 19 5-position of the phenolic ring by alkyl, haloalkyl,
450450 20 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
451451 21 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
452452 22 2-(4-morpholinyl)ethyl, whether or not substituted in the
453453 23 cyclohexyl ring to any extent. Examples of this structural
454454 24 class include, but are not limited to, CP 47, 497 and its
455455 25 C8 homologue (cannabicyclohexanol);
456456 26 (46.1) Any compound structurally derived from
457457
458458
459459
460460
461461
462462 SB2089 - 12 - LRB103 27669 RLC 57233 b
463463
464464
465465 SB2089- 13 -LRB103 27669 RLC 57233 b SB2089 - 13 - LRB103 27669 RLC 57233 b
466466 SB2089 - 13 - LRB103 27669 RLC 57233 b
467467 1 3-(benzoyl) indole with substitution at the nitrogen atom
468468 2 of the indole ring by an alkyl, haloalkyl, alkenyl,
469469 3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
470470 4 halide, 1-(N-methyl-2-piperidinyl)methyl, or
471471 5 2-(4-morpholinyl)ethyl group whether or not further
472472 6 substituted in the indole ring to any extent and whether
473473 7 or not substituted in the phenyl ring to any extent.
474474 8 Examples of this structural class include, but are not
475475 9 limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
476476 10 48,098), and RCS-4;
477477 11 (47) (Blank);
478478 12 (48) (Blank);
479479 13 (49) (Blank);
480480 14 (50) (Blank);
481481 15 (51) (Blank);
482482 16 (52) (Blank);
483483 17 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
484484 18 Some trade or other names: 2C-T-7;
485485 19 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
486486 20 trade or other names: 2C-E;
487487 21 (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
488488 22 trade or other names: 2C-D;
489489 23 (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
490490 24 trade or other names: 2C-C;
491491 25 (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
492492 26 or other names: 2C-I;
493493
494494
495495
496496
497497
498498 SB2089 - 13 - LRB103 27669 RLC 57233 b
499499
500500
501501 SB2089- 14 -LRB103 27669 RLC 57233 b SB2089 - 14 - LRB103 27669 RLC 57233 b
502502 SB2089 - 14 - LRB103 27669 RLC 57233 b
503503 1 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
504504 2 trade or other names: 2C-T-2;
505505 3 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
506506 4 Some trade or other names: 2C-T-4;
507507 5 (53.7) 2,5-dimethoxyphenethylamine. Some trade or
508508 6 other names: 2C-H;
509509 7 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
510510 8 trade or other names: 2C-N;
511511 9 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
512512 10 trade or other names: 2C-P;
513513 11 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
514514 12 Some trade or other names: 2C-G;
515515 13 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
516516 14 phenethylamine referred to in subparagraphs (20.1), (53),
517517 15 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
518518 16 (53.8), (53.9), and (53.10) including, but not limited to,
519519 17 25I-NBOMe and 25C-NBOMe;
520520 18 (54) 5-Methoxy-N,N-diisopropyltryptamine;
521521 19 (55) (Blank);
522522 20 (56) (Blank);
523523 21 (57) (Blank);
524524 22 (58) (Blank);
525525 23 (59) 3-cyclopropoylindole with substitution at the
526526 24 nitrogen atom of the indole ring by alkyl, haloalkyl,
527527 25 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
528528 26 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
529529
530530
531531
532532
533533
534534 SB2089 - 14 - LRB103 27669 RLC 57233 b
535535
536536
537537 SB2089- 15 -LRB103 27669 RLC 57233 b SB2089 - 15 - LRB103 27669 RLC 57233 b
538538 SB2089 - 15 - LRB103 27669 RLC 57233 b
539539 1 2-(4-morpholinyl)ethyl, whether or not further substituted
540540 2 on the indole ring to any extent, whether or not
541541 3 substituted on the cyclopropyl ring to any extent:
542542 4 including, but not limited to, XLR11, UR144, FUB-144;
543543 5 (60) 3-adamantoylindole with substitution at the
544544 6 nitrogen atom of the indole ring by alkyl, haloalkyl,
545545 7 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
546546 8 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
547547 9 2-(4-morpholinyl)ethyl, whether or not further substituted
548548 10 on the indole ring to any extent, whether or not
549549 11 substituted on the adamantyl ring to any extent:
550550 12 including, but not limited to, AB-001;
551551 13 (61) N-(adamantyl)-indole-3-carboxamide with
552552 14 substitution at the nitrogen atom of the indole ring by
553553 15 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
554554 16 cycloalkylethyl, aryl halide, alkyl aryl halide,
555555 17 1-(N-methyl-2-piperidinyl)methyl, or
556556 18 2-(4-morpholinyl)ethyl, whether or not further substituted
557557 19 on the indole ring to any extent, whether or not
558558 20 substituted on the adamantyl ring to any extent:
559559 21 including, but not limited to, APICA/2NE-1, STS-135;
560560 22 (62) N-(adamantyl)-indazole-3-carboxamide with
561561 23 substitution at a nitrogen atom of the indazole ring by
562562 24 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
563563 25 cycloalkylethyl, aryl halide, alkyl aryl halide,
564564 26 1-(N-methyl-2-piperidinyl)methyl, or
565565
566566
567567
568568
569569
570570 SB2089 - 15 - LRB103 27669 RLC 57233 b
571571
572572
573573 SB2089- 16 -LRB103 27669 RLC 57233 b SB2089 - 16 - LRB103 27669 RLC 57233 b
574574 SB2089 - 16 - LRB103 27669 RLC 57233 b
575575 1 2-(4-morpholinyl)ethyl, whether or not further substituted
576576 2 on the indazole ring to any extent, whether or not
577577 3 substituted on the adamantyl ring to any extent:
578578 4 including, but not limited to, AKB48, 5F-AKB48;
579579 5 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
580580 6 with substitution at the nitrogen atom of the indole ring
581581 7 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
582582 8 cycloalkylethyl, aryl halide, alkyl aryl halide,
583583 9 1-(N-methyl-2-piperidinyl)methyl, or
584584 10 2-(4-morpholinyl)ethyl, whether or not further substituted
585585 11 on the indole ring to any extent, whether or not
586586 12 substituted on the quinoline ring to any extent:
587587 13 including, but not limited to, PB22, 5F-PB22, FUB-PB-22;
588588 14 (64) 3-(1-naphthoyl)indazole with substitution at the
589589 15 nitrogen atom of the indazole ring by alkyl, haloalkyl,
590590 16 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
591591 17 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
592592 18 2-(4-morpholinyl)ethyl, whether or not further substituted
593593 19 on the indazole ring to any extent, whether or not
594594 20 substituted on the naphthyl ring to any extent: including,
595595 21 but not limited to, THJ-018, THJ-2201;
596596 22 (65) 2-(1-naphthoyl)benzimidazole with substitution
597597 23 at the nitrogen atom of the benzimidazole ring by alkyl,
598598 24 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
599599 25 aryl halide, alkyl aryl halide,
600600 26 1-(N-methyl-2-piperidinyl)methyl, or
601601
602602
603603
604604
605605
606606 SB2089 - 16 - LRB103 27669 RLC 57233 b
607607
608608
609609 SB2089- 17 -LRB103 27669 RLC 57233 b SB2089 - 17 - LRB103 27669 RLC 57233 b
610610 SB2089 - 17 - LRB103 27669 RLC 57233 b
611611 1 2-(4-morpholinyl)ethyl, whether or not further substituted
612612 2 on the benzimidazole ring to any extent, whether or not
613613 3 substituted on the naphthyl ring to any extent: including,
614614 4 but not limited to, FUBIMINA;
615615 5 (66)
616616 6 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
617617 7 3-carboxamide with substitution on the nitrogen atom of
618618 8 the indazole ring by alkyl, haloalkyl, alkenyl,
619619 9 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
620620 10 halide, 1-(N-methyl-2-piperidinyl)methyl, or
621621 11 2-(4-morpholinyl)ethyl, whether or not further substituted
622622 12 on the indazole ring to any extent: including, but not
623623 13 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
624624 14 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
625625 15 indazole-3-carboxamide with substitution on the nitrogen
626626 16 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
627627 17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
628628 18 halide, 1-(N-methyl-2-piperidinyl)methyl, or
629629 19 2-(4-morpholinyl)ethyl, whether or not further substituted
630630 20 on the indazole ring to any extent: including, but not
631631 21 limited to, ADB-PINACA, ADB-FUBINACA;
632632 22 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
633633 23 indole-3-carboxamide with substitution on the nitrogen
634634 24 atom of the indole ring by alkyl, haloalkyl, alkenyl,
635635 25 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
636636 26 halide, 1-(N-methyl-2-piperidinyl)methyl, or
637637
638638
639639
640640
641641
642642 SB2089 - 17 - LRB103 27669 RLC 57233 b
643643
644644
645645 SB2089- 18 -LRB103 27669 RLC 57233 b SB2089 - 18 - LRB103 27669 RLC 57233 b
646646 SB2089 - 18 - LRB103 27669 RLC 57233 b
647647 1 2-(4-morpholinyl)ethyl, whether or not further substituted
648648 2 on the indole ring to any extent: including, but not
649649 3 limited to, ADBICA, 5F-ADBICA;
650650 4 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
651651 5 3-carboxamide with substitution on the nitrogen atom of
652652 6 the indole ring by alkyl, haloalkyl, alkenyl,
653653 7 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
654654 8 halide, 1-(N-methyl-2-piperidinyl)methyl, or
655655 9 2-(4-morpholinyl)ethyl, whether or not further substituted
656656 10 on the indole ring to any extent: including, but not
657657 11 limited to, ABICA, 5F-ABICA;
658658 12 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
659659 13 methylbutanoate with substitution on the nitrogen atom of
660660 14 the indazole ring by alkyl, haloalkyl, alkenyl,
661661 15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
662662 16 halide, 1-(N-methyl-2-piperidinyl)methyl, or
663663 17 2-(4-morpholinyl)ethyl, whether or not further substituted
664664 18 on the indazole ring to any extent: including, but not
665665 19 limited to, AMB, 5F-AMB;
666666 20 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
667667 21 dimethylbutanoate with substitution on the nitrogen atom
668668 22 of the indazole ring by alkyl, haloalkyl, alkenyl,
669669 23 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
670670 24 halide, 1-(N-methyl-2-piperidinyl)methyl, or
671671 25 2-(4-morpholinyl)ethyl, whether or not further substituted
672672 26 on the indazole ring to any extent: including, but not
673673
674674
675675
676676
677677
678678 SB2089 - 18 - LRB103 27669 RLC 57233 b
679679
680680
681681 SB2089- 19 -LRB103 27669 RLC 57233 b SB2089 - 19 - LRB103 27669 RLC 57233 b
682682 SB2089 - 19 - LRB103 27669 RLC 57233 b
683683 1 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
684684 2 (72) Methyl 2-(1H-indole-3-carboxamido)-3-
685685 3 methylbutanoate with substitution on the nitrogen atom of
686686 4 the indole ring by alkyl, haloalkyl, alkenyl,
687687 5 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
688688 6 halide, 1-(N-methyl-2-piperidinyl)methyl, or
689689 7 2-(4-morpholinyl)ethyl, whether or not further substituted
690690 8 on the indazole ring to any extent: including, but not
691691 9 limited to, MMB018, MMB2201, and AMB-CHMICA;
692692 10 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
693693 11 dimethylbutanoate with substitution on the nitrogen atom
694694 12 of the indole ring by alkyl, haloalkyl, alkenyl,
695695 13 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
696696 14 halide, 1-(N-methyl-2-piperidinyl)methyl, or
697697 15 2-(4-morpholinyl)ethyl, whether or not further substituted
698698 16 on the indazole ring to any extent: including, but not
699699 17 limited to, MDMB-CHMICA;
700700 18 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
701701 19 indazole-3-carboxamide with substitution on the nitrogen
702702 20 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
703703 21 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
704704 22 halide, 1-(N-methyl-2-piperidinyl)methyl, or
705705 23 2-(4-morpholinyl)ethyl, whether or not further substituted
706706 24 on the indazole ring to any extent: including, but not
707707 25 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
708708 26 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
709709
710710
711711
712712
713713
714714 SB2089 - 19 - LRB103 27669 RLC 57233 b
715715
716716
717717 SB2089- 20 -LRB103 27669 RLC 57233 b SB2089 - 20 - LRB103 27669 RLC 57233 b
718718 SB2089 - 20 - LRB103 27669 RLC 57233 b
719719 1 3-carboxamide with substitution on the nitrogen atom of
720720 2 the indole ring by alkyl, haloalkyl, alkenyl,
721721 3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
722722 4 halide, 1-(N-methyl-2-piperidinyl)methyl, or
723723 5 2-(4-morpholinyl)ethyl, whether or not further substituted
724724 6 on the indazole ring to any extent: including, but not
725725 7 limited to, APP-PICA and 5-fluoro-APP-PICA;
726726 8 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
727727 9 4-AcO-DMT;
728728 10 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
729729 11 name 5-MeO-MIPT;
730730 12 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
731731 13 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
732732 14 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
733733 15 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
734734 16 (4-HO-MiPT);
735735 17 (82) Fluorophenylpiperazine;
736736 18 (83) Methoxetamine;
737737 19 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
738738 20 ethcathinone).
739739 21 (e) Unless specifically excepted or unless listed in
740740 22 another schedule, any material, compound, mixture, or
741741 23 preparation which contains any quantity of the following
742742 24 substances having a depressant effect on the central nervous
743743 25 system, including its salts, isomers, and salts of isomers
744744 26 whenever the existence of such salts, isomers, and salts of
745745
746746
747747
748748
749749
750750 SB2089 - 20 - LRB103 27669 RLC 57233 b
751751
752752
753753 SB2089- 21 -LRB103 27669 RLC 57233 b SB2089 - 21 - LRB103 27669 RLC 57233 b
754754 SB2089 - 21 - LRB103 27669 RLC 57233 b
755755 1 isomers is possible within the specific chemical designation:
756756 2 (1) mecloqualone;
757757 3 (2) methaqualone; and
758758 4 (3) gamma hydroxybutyric acid; and
759759 5 (4) xylazine.
760760 6 (f) Unless specifically excepted or unless listed in
761761 7 another schedule, any material, compound, mixture, or
762762 8 preparation which contains any quantity of the following
763763 9 substances having a stimulant effect on the central nervous
764764 10 system, including its salts, isomers, and salts of isomers:
765765 11 (1) Fenethylline;
766766 12 (2) N-ethylamphetamine;
767767 13 (3) Aminorex (some other names:
768768 14 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
769769 15 4-5-dihydro-5-phenyl-2-oxazolamine) and its
770770 16 salts, optical isomers, and salts of optical isomers;
771771 17 (4) Methcathinone (some other names:
772772 18 2-methylamino-1-phenylpropan-1-one;
773773 19 Ephedrone; 2-(methylamino)-propiophenone;
774774 20 alpha-(methylamino)propiophenone; N-methylcathinone;
775775 21 methycathinone; Monomethylpropion; UR 1431) and its
776776 22 salts, optical isomers, and salts of optical isomers;
777777 23 (5) Cathinone (some trade or other names:
778778 24 2-aminopropiophenone; alpha-aminopropiophenone;
779779 25 2-amino-1-phenyl-propanone; norephedrone);
780780 26 (6) N,N-dimethylamphetamine (also known as:
781781
782782
783783
784784
785785
786786 SB2089 - 21 - LRB103 27669 RLC 57233 b
787787
788788
789789 SB2089- 22 -LRB103 27669 RLC 57233 b SB2089 - 22 - LRB103 27669 RLC 57233 b
790790 SB2089 - 22 - LRB103 27669 RLC 57233 b
791791 1 N,N-alpha-trimethyl-benzeneethanamine;
792792 2 N,N-alpha-trimethylphenethylamine);
793793 3 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
794794 4 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
795795 5 (8) 3,4-Methylenedioxypyrovalerone (MDPV);
796796 6 (9) Halogenated amphetamines and
797797 7 methamphetamines - any compound derived from either
798798 8 amphetamine or methamphetamine through the substitution
799799 9 of a halogen on the phenyl ring, including, but not
800800 10 limited to, 2-fluoroamphetamine, 3-
801801 11 fluoroamphetamine and 4-fluoroamphetamine;
802802 12 (10) Aminopropylbenzofuran (APB):
803803 13 including 4-(2-Aminopropyl) benzofuran, 5-
804804 14 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
805805 15 benzofuran, and 7-(2-Aminopropyl) benzofuran;
806806 16 (11) Aminopropyldihydrobenzofuran (APDB):
807807 17 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
808808 18 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
809809 19 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
810810 20 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
811811 21 (12) Methylaminopropylbenzofuran
812812 22 (MAPB): including 4-(2-methylaminopropyl)
813813 23 benzofuran, 5-(2-methylaminopropyl)benzofuran,
814814 24 6-(2-methylaminopropyl)benzofuran
815815 25 and 7-(2-methylaminopropyl)benzofuran.
816816 26 (g) Temporary listing of substances subject to emergency
817817
818818
819819
820820
821821
822822 SB2089 - 22 - LRB103 27669 RLC 57233 b
823823
824824
825825 SB2089- 23 -LRB103 27669 RLC 57233 b SB2089 - 23 - LRB103 27669 RLC 57233 b
826826 SB2089 - 23 - LRB103 27669 RLC 57233 b
827827 1 scheduling. Any material, compound, mixture, or preparation
828828 2 that contains any quantity of the following substances:
829829 3 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
830830 4 (benzylfentanyl), its optical isomers, isomers, salts, and
831831 5 salts of isomers;
832832 6 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
833833 7 phenylpropanamide (thenylfentanyl), its optical isomers,
834834 8 salts, and salts of isomers.
835835 9 (h) Synthetic cathinones. Unless specifically excepted,
836836 10 any chemical compound which is not approved by the United
837837 11 States Food and Drug Administration or, if approved, is not
838838 12 dispensed or possessed in accordance with State or federal
839839 13 law, not including bupropion, structurally derived from
840840 14 2-aminopropan-1-one by substitution at the 1-position with
841841 15 either phenyl, naphthyl, or thiophene ring systems, whether or
842842 16 not the compound is further modified in one or more of the
843843 17 following ways:
844844 18 (1) by substitution in the ring system to any extent
845845 19 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
846846 20 halide substituents, whether or not further substituted in
847847 21 the ring system by one or more other univalent
848848 22 substituents. Examples of this class include, but are not
849849 23 limited to, 3,4-Methylenedioxycathinone (bk-MDA);
850850 24 (2) by substitution at the 3-position with an acyclic
851851 25 alkyl substituent. Examples of this class include, but are
852852 26 not limited to, 2-methylamino-1-phenylbutan-1-one
853853
854854
855855
856856
857857
858858 SB2089 - 23 - LRB103 27669 RLC 57233 b
859859
860860
861861 SB2089- 24 -LRB103 27669 RLC 57233 b SB2089 - 24 - LRB103 27669 RLC 57233 b
862862 SB2089 - 24 - LRB103 27669 RLC 57233 b
863863 1 (buphedrone); or
864864 2 (3) by substitution at the 2-amino nitrogen atom with
865865 3 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
866866 4 inclusion of the 2-amino nitrogen atom in a cyclic
867867 5 structure. Examples of this class include, but are not
868868 6 limited to, Dimethylcathinone, Ethcathinone, and
869869 7 a-Pyrrolidinopropiophenone (a-PPP); or
870870 8 Any other synthetic cathinone which is not approved by the
871871 9 United States Food and Drug Administration or, if approved, is
872872 10 not dispensed or possessed in accordance with State or federal
873873 11 law.
874874 12 (i) Synthetic cannabinoids or piperazines. Any synthetic
875875 13 cannabinoid or piperazine which is not approved by the United
876876 14 States Food and Drug Administration or, if approved, which is
877877 15 not dispensed or possessed in accordance with State and
878878 16 federal law.
879879 17 (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
880880 18 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
881881 19 8-14-18.)
882882 20 (720 ILCS 570/401) (from Ch. 56 1/2, par. 1401)
883883 21 Sec. 401. Manufacture or delivery, or possession with
884884 22 intent to manufacture or deliver, a controlled substance, a
885885 23 counterfeit substance, or controlled substance analog. Except
886886 24 as authorized by this Act, it is unlawful for any person
887887 25 knowingly to manufacture or deliver, or possess with intent to
888888
889889
890890
891891
892892
893893 SB2089 - 24 - LRB103 27669 RLC 57233 b
894894
895895
896896 SB2089- 25 -LRB103 27669 RLC 57233 b SB2089 - 25 - LRB103 27669 RLC 57233 b
897897 SB2089 - 25 - LRB103 27669 RLC 57233 b
898898 1 manufacture or deliver, a controlled substance other than
899899 2 methamphetamine and other than bath salts as defined in the
900900 3 Bath Salts Prohibition Act sold or offered for sale in a retail
901901 4 mercantile establishment as defined in Section 16-0.1 of the
902902 5 Criminal Code of 2012, a counterfeit substance, or a
903903 6 controlled substance analog. A violation of this Act with
904904 7 respect to each of the controlled substances listed herein
905905 8 constitutes a single and separate violation of this Act. For
906906 9 purposes of this Section, "controlled substance analog" or
907907 10 "analog" means a substance, other than a controlled substance,
908908 11 which is not approved by the United States Food and Drug
909909 12 Administration or, if approved, is not dispensed or possessed
910910 13 in accordance with State or federal law, and that has a
911911 14 chemical structure substantially similar to that of a
912912 15 controlled substance in Schedule I or II, or that was
913913 16 specifically designed to produce an effect substantially
914914 17 similar to that of a controlled substance in Schedule I or II.
915915 18 Examples of chemical classes in which controlled substance
916916 19 analogs are found include, but are not limited to, the
917917 20 following: phenethylamines, N-substituted piperidines,
918918 21 morphinans, ecgonines, quinazolinones, substituted indoles,
919919 22 and arylcycloalkylamines. For purposes of this Act, a
920920 23 controlled substance analog shall be treated in the same
921921 24 manner as the controlled substance to which it is
922922 25 substantially similar.
923923 26 (a) Any person who violates this Section with respect to
924924
925925
926926
927927
928928
929929 SB2089 - 25 - LRB103 27669 RLC 57233 b
930930
931931
932932 SB2089- 26 -LRB103 27669 RLC 57233 b SB2089 - 26 - LRB103 27669 RLC 57233 b
933933 SB2089 - 26 - LRB103 27669 RLC 57233 b
934934 1 the following amounts of controlled or counterfeit substances
935935 2 or controlled substance analogs, notwithstanding any of the
936936 3 provisions of subsections (c), (d), (e), (f), (g) or (h) to the
937937 4 contrary, is guilty of a Class X felony and shall be sentenced
938938 5 to a term of imprisonment as provided in this subsection (a)
939939 6 and fined as provided in subsection (b):
940940 7 (1)(A) not less than 6 years and not more than 30 years
941941 8 with respect to 15 grams or more but less than 100 grams of
942942 9 a substance containing heroin, or an analog thereof;
943943 10 (B) not less than 9 years and not more than 40 years
944944 11 with respect to 100 grams or more but less than 400 grams
945945 12 of a substance containing heroin, or an analog thereof;
946946 13 (C) not less than 12 years and not more than 50 years
947947 14 with respect to 400 grams or more but less than 900 grams
948948 15 of a substance containing heroin, or an analog thereof;
949949 16 (D) not less than 15 years and not more than 60 years
950950 17 with respect to 900 grams or more of any substance
951951 18 containing heroin, or an analog thereof;
952952 19 (1.5)(A) not less than 6 years and not more than 30
953953 20 years with respect to 15 grams or more but less than 100
954954 21 grams of a substance containing fentanyl or xylazine, or
955955 22 an analog thereof;
956956 23 (B) not less than 9 years and not more than 40 years
957957 24 with respect to 100 grams or more but less than 400 grams
958958 25 of a substance containing fentanyl or xylazine, or an
959959 26 analog thereof;
960960
961961
962962
963963
964964
965965 SB2089 - 26 - LRB103 27669 RLC 57233 b
966966
967967
968968 SB2089- 27 -LRB103 27669 RLC 57233 b SB2089 - 27 - LRB103 27669 RLC 57233 b
969969 SB2089 - 27 - LRB103 27669 RLC 57233 b
970970 1 (C) not less than 12 years and not more than 50 years
971971 2 with respect to 400 grams or more but less than 900 grams
972972 3 of a substance containing fentanyl or xylazine, or an
973973 4 analog thereof;
974974 5 (D) not less than 15 years and not more than 60 years
975975 6 with respect to 900 grams or more of a substance
976976 7 containing fentanyl or xylazine, or an analog thereof;
977977 8 (2)(A) not less than 6 years and not more than 30 years
978978 9 with respect to 15 grams or more but less than 100 grams of
979979 10 a substance containing cocaine, or an analog thereof;
980980 11 (B) not less than 9 years and not more than 40 years
981981 12 with respect to 100 grams or more but less than 400 grams
982982 13 of a substance containing cocaine, or an analog thereof;
983983 14 (C) not less than 12 years and not more than 50 years
984984 15 with respect to 400 grams or more but less than 900 grams
985985 16 of a substance containing cocaine, or an analog thereof;
986986 17 (D) not less than 15 years and not more than 60 years
987987 18 with respect to 900 grams or more of any substance
988988 19 containing cocaine, or an analog thereof;
989989 20 (3)(A) not less than 6 years and not more than 30 years
990990 21 with respect to 15 grams or more but less than 100 grams of
991991 22 a substance containing morphine, or an analog thereof;
992992 23 (B) not less than 9 years and not more than 40 years
993993 24 with respect to 100 grams or more but less than 400 grams
994994 25 of a substance containing morphine, or an analog thereof;
995995 26 (C) not less than 12 years and not more than 50 years
996996
997997
998998
999999
10001000
10011001 SB2089 - 27 - LRB103 27669 RLC 57233 b
10021002
10031003
10041004 SB2089- 28 -LRB103 27669 RLC 57233 b SB2089 - 28 - LRB103 27669 RLC 57233 b
10051005 SB2089 - 28 - LRB103 27669 RLC 57233 b
10061006 1 with respect to 400 grams or more but less than 900 grams
10071007 2 of a substance containing morphine, or an analog thereof;
10081008 3 (D) not less than 15 years and not more than 60 years
10091009 4 with respect to 900 grams or more of a substance
10101010 5 containing morphine, or an analog thereof;
10111011 6 (4) 200 grams or more of any substance containing
10121012 7 peyote, or an analog thereof;
10131013 8 (5) 200 grams or more of any substance containing a
10141014 9 derivative of barbituric acid or any of the salts of a
10151015 10 derivative of barbituric acid, or an analog thereof;
10161016 11 (6) 200 grams or more of any substance containing
10171017 12 amphetamine or any salt of an optical isomer of
10181018 13 amphetamine, or an analog thereof;
10191019 14 (6.5) (blank);
10201020 15 (6.6) (blank);
10211021 16 (7)(A) not less than 6 years and not more than 30 years
10221022 17 with respect to: (i) 15 grams or more but less than 100
10231023 18 grams of a substance containing lysergic acid diethylamide
10241024 19 (LSD), or an analog thereof, or (ii) 15 or more objects or
10251025 20 15 or more segregated parts of an object or objects but
10261026 21 less than 200 objects or 200 segregated parts of an object
10271027 22 or objects containing in them or having upon them any
10281028 23 amounts of any substance containing lysergic acid
10291029 24 diethylamide (LSD), or an analog thereof;
10301030 25 (B) not less than 9 years and not more than 40 years
10311031 26 with respect to: (i) 100 grams or more but less than 400
10321032
10331033
10341034
10351035
10361036
10371037 SB2089 - 28 - LRB103 27669 RLC 57233 b
10381038
10391039
10401040 SB2089- 29 -LRB103 27669 RLC 57233 b SB2089 - 29 - LRB103 27669 RLC 57233 b
10411041 SB2089 - 29 - LRB103 27669 RLC 57233 b
10421042 1 grams of a substance containing lysergic acid diethylamide
10431043 2 (LSD), or an analog thereof, or (ii) 200 or more objects or
10441044 3 200 or more segregated parts of an object or objects but
10451045 4 less than 600 objects or less than 600 segregated parts of
10461046 5 an object or objects containing in them or having upon
10471047 6 them any amount of any substance containing lysergic acid
10481048 7 diethylamide (LSD), or an analog thereof;
10491049 8 (C) not less than 12 years and not more than 50 years
10501050 9 with respect to: (i) 400 grams or more but less than 900
10511051 10 grams of a substance containing lysergic acid diethylamide
10521052 11 (LSD), or an analog thereof, or (ii) 600 or more objects or
10531053 12 600 or more segregated parts of an object or objects but
10541054 13 less than 1500 objects or 1500 segregated parts of an
10551055 14 object or objects containing in them or having upon them
10561056 15 any amount of any substance containing lysergic acid
10571057 16 diethylamide (LSD), or an analog thereof;
10581058 17 (D) not less than 15 years and not more than 60 years
10591059 18 with respect to: (i) 900 grams or more of any substance
10601060 19 containing lysergic acid diethylamide (LSD), or an analog
10611061 20 thereof, or (ii) 1500 or more objects or 1500 or more
10621062 21 segregated parts of an object or objects containing in
10631063 22 them or having upon them any amount of a substance
10641064 23 containing lysergic acid diethylamide (LSD), or an analog
10651065 24 thereof;
10661066 25 (7.5)(A) not less than 6 years and not more than 30 years
10671067 26 with respect to: (i) 15 grams or more but less than 100
10681068
10691069
10701070
10711071
10721072
10731073 SB2089 - 29 - LRB103 27669 RLC 57233 b
10741074
10751075
10761076 SB2089- 30 -LRB103 27669 RLC 57233 b SB2089 - 30 - LRB103 27669 RLC 57233 b
10771077 SB2089 - 30 - LRB103 27669 RLC 57233 b
10781078 1 grams of a substance listed in paragraph (1), (2), (2.1),
10791079 2 (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
10801080 3 (26) of subsection (d) of Section 204, or an analog or
10811081 4 derivative thereof, or (ii) 15 or more pills, tablets,
10821082 5 caplets, capsules, or objects but less than 200 pills,
10831083 6 tablets, caplets, capsules, or objects containing in them
10841084 7 or having upon them any amounts of any substance listed in
10851085 8 paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
10861086 9 (20.1), (21), (25), or (26) of subsection (d) of Section
10871087 10 204, or an analog or derivative thereof;
10881088 11 (B) not less than 9 years and not more than 40 years
10891089 12 with respect to: (i) 100 grams or more but less than 400
10901090 13 grams of a substance listed in paragraph (1), (2), (2.1),
10911091 14 (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
10921092 15 (26) of subsection (d) of Section 204, or an analog or
10931093 16 derivative thereof, or (ii) 200 or more pills, tablets,
10941094 17 caplets, capsules, or objects but less than 600 pills,
10951095 18 tablets, caplets, capsules, or objects containing in them
10961096 19 or having upon them any amount of any substance listed in
10971097 20 paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
10981098 21 (20.1), (21), (25), or (26) of subsection (d) of Section
10991099 22 204, or an analog or derivative thereof;
11001100 23 (C) not less than 12 years and not more than 50 years
11011101 24 with respect to: (i) 400 grams or more but less than 900
11021102 25 grams of a substance listed in paragraph (1), (2), (2.1),
11031103 26 (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
11041104
11051105
11061106
11071107
11081108
11091109 SB2089 - 30 - LRB103 27669 RLC 57233 b
11101110
11111111
11121112 SB2089- 31 -LRB103 27669 RLC 57233 b SB2089 - 31 - LRB103 27669 RLC 57233 b
11131113 SB2089 - 31 - LRB103 27669 RLC 57233 b
11141114 1 (26) of subsection (d) of Section 204, or an analog or
11151115 2 derivative thereof, or (ii) 600 or more pills, tablets,
11161116 3 caplets, capsules, or objects but less than 1,500 pills,
11171117 4 tablets, caplets, capsules, or objects containing in them
11181118 5 or having upon them any amount of any substance listed in
11191119 6 paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
11201120 7 (20.1), (21), (25), or (26) of subsection (d) of Section
11211121 8 204, or an analog or derivative thereof;
11221122 9 (D) not less than 15 years and not more than 60 years
11231123 10 with respect to: (i) 900 grams or more of any substance
11241124 11 listed in paragraph (1), (2), (2.1), (2.2), (3), (14.1),
11251125 12 (19), (20), (20.1), (21), (25), or (26) of subsection (d)
11261126 13 of Section 204, or an analog or derivative thereof, or
11271127 14 (ii) 1,500 or more pills, tablets, caplets, capsules, or
11281128 15 objects containing in them or having upon them any amount
11291129 16 of a substance listed in paragraph (1), (2), (2.1), (2.2),
11301130 17 (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
11311131 18 subsection (d) of Section 204, or an analog or derivative
11321132 19 thereof;
11331133 20 (8) 30 grams or more of any substance containing
11341134 21 pentazocine or any of the salts, isomers and salts of
11351135 22 isomers of pentazocine, or an analog thereof;
11361136 23 (9) 30 grams or more of any substance containing
11371137 24 methaqualone or any of the salts, isomers and salts of
11381138 25 isomers of methaqualone, or an analog thereof;
11391139 26 (10) 30 grams or more of any substance containing
11401140
11411141
11421142
11431143
11441144
11451145 SB2089 - 31 - LRB103 27669 RLC 57233 b
11461146
11471147
11481148 SB2089- 32 -LRB103 27669 RLC 57233 b SB2089 - 32 - LRB103 27669 RLC 57233 b
11491149 SB2089 - 32 - LRB103 27669 RLC 57233 b
11501150 1 phencyclidine or any of the salts, isomers and salts of
11511151 2 isomers of phencyclidine (PCP), or an analog thereof;
11521152 3 (10.5) 30 grams or more of any substance containing
11531153 4 ketamine or any of the salts, isomers and salts of isomers
11541154 5 of ketamine, or an analog thereof;
11551155 6 (10.6) 100 grams or more of any substance containing
11561156 7 hydrocodone, or any of the salts, isomers and salts of
11571157 8 isomers of hydrocodone, or an analog thereof;
11581158 9 (10.7) (blank);
11591159 10 (10.8) 100 grams or more of any substance containing
11601160 11 dihydrocodeine, or any of the salts, isomers and salts of
11611161 12 isomers of dihydrocodeine, or an analog thereof;
11621162 13 (10.9) 100 grams or more of any substance containing
11631163 14 oxycodone, or any of the salts, isomers and salts of
11641164 15 isomers of oxycodone, or an analog thereof;
11651165 16 (11) 200 grams or more of any substance containing any
11661166 17 other controlled substance classified in Schedules I or
11671167 18 II, or an analog thereof, which is not otherwise included
11681168 19 in this subsection.
11691169 20 (b) Any person sentenced with respect to violations of
11701170 21 paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
11711171 22 involving 100 grams or more of the controlled substance named
11721172 23 therein, may in addition to the penalties provided therein, be
11731173 24 fined an amount not more than $500,000 or the full street value
11741174 25 of the controlled or counterfeit substance or controlled
11751175 26 substance analog, whichever is greater. The term "street
11761176
11771177
11781178
11791179
11801180
11811181 SB2089 - 32 - LRB103 27669 RLC 57233 b
11821182
11831183
11841184 SB2089- 33 -LRB103 27669 RLC 57233 b SB2089 - 33 - LRB103 27669 RLC 57233 b
11851185 SB2089 - 33 - LRB103 27669 RLC 57233 b
11861186 1 value" shall have the meaning ascribed in Section 110-5 of the
11871187 2 Code of Criminal Procedure of 1963. Any person sentenced with
11881188 3 respect to any other provision of subsection (a), may in
11891189 4 addition to the penalties provided therein, be fined an amount
11901190 5 not to exceed $500,000.
11911191 6 (b-1) Excluding violations of this Act when the controlled
11921192 7 substance is fentanyl, any person sentenced to a term of
11931193 8 imprisonment with respect to violations of Section 401, 401.1,
11941194 9 405, 405.1, 405.2, or 407, when the substance containing the
11951195 10 controlled substance contains any amount of fentanyl, 3 years
11961196 11 shall be added to the term of imprisonment imposed by the
11971197 12 court, and the maximum sentence for the offense shall be
11981198 13 increased by 3 years.
11991199 14 (c) Any person who violates this Section with regard to
12001200 15 the following amounts of controlled or counterfeit substances
12011201 16 or controlled substance analogs, notwithstanding any of the
12021202 17 provisions of subsections (a), (b), (d), (e), (f), (g) or (h)
12031203 18 to the contrary, is guilty of a Class 1 felony. The fine for
12041204 19 violation of this subsection (c) shall not be more than
12051205 20 $250,000:
12061206 21 (1) 1 gram or more but less than 15 grams of any
12071207 22 substance containing heroin, or an analog thereof;
12081208 23 (1.5) 1 gram or more but less than 15 grams of any
12091209 24 substance containing fentanyl, or an analog thereof;
12101210 25 (2) 1 gram or more but less than 15 grams of any
12111211 26 substance containing cocaine, or an analog thereof;
12121212
12131213
12141214
12151215
12161216
12171217 SB2089 - 33 - LRB103 27669 RLC 57233 b
12181218
12191219
12201220 SB2089- 34 -LRB103 27669 RLC 57233 b SB2089 - 34 - LRB103 27669 RLC 57233 b
12211221 SB2089 - 34 - LRB103 27669 RLC 57233 b
12221222 1 (2.5) 1 gram or more but less than 15 grams of any
12231223 2 substance containing xylazine, or an analog thereof;
12241224 3 (3) 10 grams or more but less than 15 grams of any
12251225 4 substance containing morphine, or an analog thereof;
12261226 5 (4) 50 grams or more but less than 200 grams of any
12271227 6 substance containing peyote, or an analog thereof;
12281228 7 (5) 50 grams or more but less than 200 grams of any
12291229 8 substance containing a derivative of barbituric acid or
12301230 9 any of the salts of a derivative of barbituric acid, or an
12311231 10 analog thereof;
12321232 11 (6) 50 grams or more but less than 200 grams of any
12331233 12 substance containing amphetamine or any salt of an optical
12341234 13 isomer of amphetamine, or an analog thereof;
12351235 14 (6.5) (blank);
12361236 15 (7)(i) 5 grams or more but less than 15 grams of any
12371237 16 substance containing lysergic acid diethylamide (LSD), or
12381238 17 an analog thereof, or (ii) more than 10 objects or more
12391239 18 than 10 segregated parts of an object or objects but less
12401240 19 than 15 objects or less than 15 segregated parts of an
12411241 20 object containing in them or having upon them any amount
12421242 21 of any substance containing lysergic acid diethylamide
12431243 22 (LSD), or an analog thereof;
12441244 23 (7.5)(i) 5 grams or more but less than 15 grams of any
12451245 24 substance listed in paragraph (1), (2), (2.1), (2.2), (3),
12461246 25 (14.1), (19), (20), (20.1), (21), (25), or (26) of
12471247 26 subsection (d) of Section 204, or an analog or derivative
12481248
12491249
12501250
12511251
12521252
12531253 SB2089 - 34 - LRB103 27669 RLC 57233 b
12541254
12551255
12561256 SB2089- 35 -LRB103 27669 RLC 57233 b SB2089 - 35 - LRB103 27669 RLC 57233 b
12571257 SB2089 - 35 - LRB103 27669 RLC 57233 b
12581258 1 thereof, or (ii) more than 10 pills, tablets, caplets,
12591259 2 capsules, or objects but less than 15 pills, tablets,
12601260 3 caplets, capsules, or objects containing in them or having
12611261 4 upon them any amount of any substance listed in paragraph
12621262 5 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
12631263 6 (21), (25), or (26) of subsection (d) of Section 204, or an
12641264 7 analog or derivative thereof;
12651265 8 (8) 10 grams or more but less than 30 grams of any
12661266 9 substance containing pentazocine or any of the salts,
12671267 10 isomers and salts of isomers of pentazocine, or an analog
12681268 11 thereof;
12691269 12 (9) 10 grams or more but less than 30 grams of any
12701270 13 substance containing methaqualone or any of the salts,
12711271 14 isomers and salts of isomers of methaqualone, or an analog
12721272 15 thereof;
12731273 16 (10) 10 grams or more but less than 30 grams of any
12741274 17 substance containing phencyclidine or any of the salts,
12751275 18 isomers and salts of isomers of phencyclidine (PCP), or an
12761276 19 analog thereof;
12771277 20 (10.5) 10 grams or more but less than 30 grams of any
12781278 21 substance containing ketamine or any of the salts, isomers
12791279 22 and salts of isomers of ketamine, or an analog thereof;
12801280 23 (10.6) 50 grams or more but less than 100 grams of any
12811281 24 substance containing hydrocodone, or any of the salts,
12821282 25 isomers and salts of isomers of hydrocodone, or an analog
12831283 26 thereof;
12841284
12851285
12861286
12871287
12881288
12891289 SB2089 - 35 - LRB103 27669 RLC 57233 b
12901290
12911291
12921292 SB2089- 36 -LRB103 27669 RLC 57233 b SB2089 - 36 - LRB103 27669 RLC 57233 b
12931293 SB2089 - 36 - LRB103 27669 RLC 57233 b
12941294 1 (10.7) (blank);
12951295 2 (10.8) 50 grams or more but less than 100 grams of any
12961296 3 substance containing dihydrocodeine, or any of the salts,
12971297 4 isomers and salts of isomers of dihydrocodeine, or an
12981298 5 analog thereof;
12991299 6 (10.9) 50 grams or more but less than 100 grams of any
13001300 7 substance containing oxycodone, or any of the salts,
13011301 8 isomers and salts of isomers of oxycodone, or an analog
13021302 9 thereof;
13031303 10 (11) 50 grams or more but less than 200 grams of any
13041304 11 substance containing a substance classified in Schedules I
13051305 12 or II, or an analog thereof, which is not otherwise
13061306 13 included in this subsection.
13071307 14 (c-5) (Blank).
13081308 15 (d) Any person who violates this Section with regard to
13091309 16 any other amount of a controlled or counterfeit substance
13101310 17 containing dihydrocodeine or classified in Schedules I or II,
13111311 18 or an analog thereof, which is (i) a narcotic drug, (ii)
13121312 19 lysergic acid diethylamide (LSD) or an analog thereof, (iii)
13131313 20 any substance containing amphetamine or fentanyl or xylazine
13141314 21 or any salt or optical isomer of amphetamine or fentanyl or
13151315 22 xylazine, or an analog thereof, or (iv) any substance
13161316 23 containing N-Benzylpiperazine (BZP) or any salt or optical
13171317 24 isomer of N-Benzylpiperazine (BZP), or an analog thereof, is
13181318 25 guilty of a Class 2 felony. The fine for violation of this
13191319 26 subsection (d) shall not be more than $200,000.
13201320
13211321
13221322
13231323
13241324
13251325 SB2089 - 36 - LRB103 27669 RLC 57233 b
13261326
13271327
13281328 SB2089- 37 -LRB103 27669 RLC 57233 b SB2089 - 37 - LRB103 27669 RLC 57233 b
13291329 SB2089 - 37 - LRB103 27669 RLC 57233 b
13301330 1 (d-5) (Blank).
13311331 2 (e) Any person who violates this Section with regard to
13321332 3 any other amount of a controlled substance other than
13331333 4 methamphetamine or counterfeit substance classified in
13341334 5 Schedule I or II, or an analog thereof, which substance is not
13351335 6 included under subsection (d) of this Section, is guilty of a
13361336 7 Class 3 felony. The fine for violation of this subsection (e)
13371337 8 shall not be more than $150,000.
13381338 9 (f) Any person who violates this Section with regard to
13391339 10 any other amount of a controlled or counterfeit substance
13401340 11 classified in Schedule III is guilty of a Class 3 felony. The
13411341 12 fine for violation of this subsection (f) shall not be more
13421342 13 than $125,000.
13431343 14 (g) Any person who violates this Section with regard to
13441344 15 any other amount of a controlled or counterfeit substance
13451345 16 classified in Schedule IV is guilty of a Class 3 felony. The
13461346 17 fine for violation of this subsection (g) shall not be more
13471347 18 than $100,000.
13481348 19 (h) Any person who violates this Section with regard to
13491349 20 any other amount of a controlled or counterfeit substance
13501350 21 classified in Schedule V is guilty of a Class 3 felony. The
13511351 22 fine for violation of this subsection (h) shall not be more
13521352 23 than $75,000.
13531353 24 (i) This Section does not apply to the manufacture,
13541354 25 possession or distribution of a substance in conformance with
13551355 26 the provisions of an approved new drug application or an
13561356
13571357
13581358
13591359
13601360
13611361 SB2089 - 37 - LRB103 27669 RLC 57233 b
13621362
13631363
13641364 SB2089- 38 -LRB103 27669 RLC 57233 b SB2089 - 38 - LRB103 27669 RLC 57233 b
13651365 SB2089 - 38 - LRB103 27669 RLC 57233 b
13661366 1 exemption for investigational use within the meaning of
13671367 2 Section 505 of the Federal Food, Drug and Cosmetic Act.
13681368 3 (j) (Blank).
13691369 4 (Source: P.A. 99-371, eff. 1-1-16; 99-585, eff. 1-1-17;
13701370 5 100-368, eff. 1-1-18.)
13711371
13721372
13731373
13741374
13751375
13761376 SB2089 - 38 - LRB103 27669 RLC 57233 b